Randomised evaluation of assertive community treatment: 3-year outcomes, The British Journal of Psychiatry (2009) 195: 81-82.
Helen Killaspy, PhD, MRCPsych
Department of Mental Health Sciences, University College London (UCL) Medical School, Hampstead Campus and Camden and Islington NHS Foundation Trust, London
Stella Kingett, MRCPsych
Camden and Islington NHS Foundation Trust, London
Paul Bebbington, PhD, FRCP, FRCPsych
Department of Mental Health Sciences, UCL Medical School, Bloomsbury Campus and Camden and Islington NHS Foundation Trust, London
Robert Blizard, BSc, MSc, FRSS
Department of Mental Health Sciences, UCL Medical School, Hampstead Campus, London
Sonia Johnson, DM, MRCPsych
Department of Mental Health Sciences, UCL Medical School, Bloomsbury Campus and Camden and Islington NHS Foundation Trust, London
Fiona Nolan, BSc and Stephen Pilling, BSc, MSc PhD
Centre for Outcomes Research and Effectiveness, UCL, Torrington Place, London
Michael King, PhD, FRCP, FRCGP, FRCPsych
Department of Mental Health Sciences, University College London (UCL) Medical School, Hampstead Campus and Camden and Islington NHS Foundation Trust, London, UK
Abstract:
The only randomised controlled trial to test high-fidelity assertive community treatment (ACT) in the UK (the Randomised Evaluation of Assertive Community Treatment (REACT) study) found no advantage over usual care from community mental health teams in reducing the need for in-patient care and in other clinical outcomes, but participants found ACT more acceptable and engaged better with it. One possible reason for the lack of efficacy of ACT might be the short period of follow-up (18 months in the REACT study). This paper reports on participants’ service contact, in-patient service use and adverse events 36 months after randomisation.
Lancashire Care staff can request the full-text of this paper, email: susan.jennings@lancashirecare.nhs.uk
Filed under: Assertive Outreach
